Notice of Proposed Sale · 144

Regeneron Pharmaceuticals, Inc.

REGNNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Sep 2, 2026Accepted Sep 2, 2026, 4:09 PM EDTFiling CIK 872589Accession 0001969223-26-000987

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: REGENERON PHARMACEUTICALS, INC.
Issuer CIK: 0000872589
SEC file number: 000-19034
Phone: 9148477000
Person for whose account securities are to be sold: Guarini Kathryn
Relationships to issuer: Director
Street: 777 OLD SAW MILL RIVER ROAD
City: TARRYTOWN
State / country code: NY
Postal code: 10591

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	400	340,000.00	101,137,842	09/02/2026	Nasdaq	UBS Financial Services, Inc.

Broker / market maker — proposed row 1, entry 1

Name: UBS Financial Services, Inc.
Street: Eleven Madison Avenue
Street (continued): 4th Floor
City: New York
State / country code: NY
Postal code: 10010

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	09/02/2026	Exercise of stock option	Issuer	400	N	09/02/2026	Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
Kathryn Guarini	Common	08/10/2026	400	320,000.00

Seller — prior-sale row 1, entry 1

Name: Kathryn Guarini
Street: 777 OLD SAW MILL RIVER ROAD
City: TARRYTOWN
State / country code: NY
Postal code: 10591

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 09/02/2026
Signed: /s/ UBS Financial Services Inc., as attorney-in-fact for Kathryn Guarini
Plan adoption dates: 02/13/2026

Company context

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Current securities

REGNNASDAQ · EQUITY · Current

Get the free weekly BCS email.